New drug doses tested for rare blood cancer
NCT ID NCT05978739
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This phase 2 trial tested two different daily doses of the drug orelabrutinib in 40 people with mantle cell lymphoma, a rare blood cancer. The goal was to see which dose works better at shrinking tumors and controlling the disease. Participants included both newly diagnosed and relapsed patients.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Orelabrutinib
What this could lead to
If successful, this could help determine the best dose of orelabrutinib to control mantle cell lymphoma with fewer side effects.
What could go wrong
This is a small, early-phase trial with only 40 participants. Results may not apply to all patients, and the drug may not work as well as hoped or could cause unexpected side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MANTLE CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Chenzhou First People's Hospital
Chenzhou, Hunan, 423003, China
-
Chongqing Cancer Hospital
Chongqing, Chongqing Municipality, 400030, China
-
Henan Cancer Hospital
Zhengzhou, Henan, 450003, China
-
Hubei Cancer Hospital
Wuhan, Hubei, 430079, China
-
Hunan Cancer Hospital
Changsha, Hunan, 410031, China
-
Jiangxi Cancer Hospital
Nanchang, Jiangxi, 330029, China
-
Nanyang Second General Hospital
Nanyang, Henan, 473009, China
-
Peking University Third Hospital
Beijing, Beijing Municipality, 100191, China
-
Shanxi Provincial Cancer Hospital
Taiyuan, Shanxi, 030013, China
-
Sun Yat-sen University Cancer Center
Guangdong, Guangzhou, 510055, China
-
The Affiliated Cancer Hospital of Xinjiang Medical University
Ürümqi, Uygur Autonomous Region, 830000, China
-
The First Affiliated Hospital of Anhui Medical University
Hefei, Anhui, 230022, China
-
The First Affiliated Hospital of Bengbu Medical College
Bengbu, Anhui, 233040, China
-
The First Affiliated Hospital of China Medical University
Shenyang, Liaoning, 110001, China
-
The First Affiliated Hospital of Zhejiang University School of Medicine
Hangzhou, Zhejiang, 310003, China
-
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, 450052, China
-
The Second Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, 330006, China
-
The Second Affiliated Hospital of Xi'an Jiaotong University
Xi’an, Shanxi, 710004, China
-
The Second Hospital of Dalian Medical University
Dalian, Liaoning, 116023, China
-
Union Hospital Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, 430022, China